“However, as professionals involved in SMA research, diagnosis and patient care in Scotland, we believe that all of the necessary data, evidence, and therapeutic approvals are in place to justify the inclusion of SMA on NBS programmes in Scotland. The inclusion of NBS for SMA would provide the best possible quality of life for SMA patients and their families, whilst maximising the (not insignificant) return on investment that society makes in providing access to SMN-restoring therapies.”